Gilead Sciences, Inc. (NASDAQ: GILD) Stock Competitors & Peer Comparison
See GILD's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - General Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for GILD and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| GILD | $150.18 | -0.50% | 188.7B | -390.28 | -$0.39 | +2.13% |
| LLY | $1,178.64 | -0.41% | 1.1T | 37.65 | $31.49 | +0.56% |
| JNJ | $266.72 | -1.66% | 655.6B | 25.35 | $10.73 | +1.94% |
| ABBV | $262.90 | -0.54% | 470.7B | 26.14 | $10.19 | +2.56% |
| MRK | $148.20 | -0.39% | 367.3B | 46.32 | $3.21 | +2.29% |
| NVS | $144.76 | -0.48% | 279.3B | 16.91 | $8.69 | +3.23% |
| AZN | $163.60 | -1.79% | 257.9B | 17.96 | $9.26 | +1.94% |
| AMGN | $418.19 | +0.86% | 225.7B | 18.69 | $22.37 | +2.38% |
| NVO | $38.16 | -1.66% | 171.9B | 9.63 | $4.02 | +4.65% |
| PFE | $28.44 | -0.80% | 163.7B | 9.42 | $3.05 | +5.98% |
Stock Comparison
Eli Lilly and Company (NYSE: LLY)
GILD vs LLY Comparison September 2026
Gilead Sciences, Inc. (NASDAQ: GILD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GILD stands at 188.7B. In comparison, LLY has a market cap of 1.1T. Regarding current trading prices, GILD is priced at $150.18 on the NASDAQ, while LLY trades at $1,178.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GILD currently has a P/E ratio of -390.28, whereas LLY's P/E ratio is 37.65. In terms of profitability, GILD's ROE is -0.16%, compared to LLY's ROE of +0.93%. Regarding short-term risk, GILD is more volatile compared to LLY. This indicates higher risk in terms of short-term price fluctuations for GILD.Check LLY's competition here
Johnson & Johnson (NYSE: JNJ)
GILD vs JNJ Comparison September 2026
Gilead Sciences, Inc. (NASDAQ: GILD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GILD stands at 188.7B. In comparison, JNJ has a market cap of 655.6B. Regarding current trading prices, GILD is priced at $150.18 on the NASDAQ, while JNJ trades at $266.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GILD currently has a P/E ratio of -390.28, whereas JNJ's P/E ratio is 25.35. In terms of profitability, GILD's ROE is -0.16%, compared to JNJ's ROE of +0.26%. Regarding short-term risk, GILD is more volatile compared to JNJ. This indicates higher risk in terms of short-term price fluctuations for GILD.Check JNJ's competition here
AbbVie Inc. (NYSE: ABBV)
GILD vs ABBV Comparison September 2026
Gilead Sciences, Inc. (NASDAQ: GILD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GILD stands at 188.7B. In comparison, ABBV has a market cap of 470.7B. Regarding current trading prices, GILD is priced at $150.18 on the NASDAQ, while ABBV trades at $262.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GILD currently has a P/E ratio of -390.28, whereas ABBV's P/E ratio is 26.14. In terms of profitability, GILD's ROE is -0.16%, compared to ABBV's ROE of -1.36%. Regarding short-term risk, GILD is less volatile compared to ABBV. This indicates lower risk in terms of short-term price fluctuations for GILD.Check ABBV's competition here
Merck & Co., Inc. (NYSE: MRK)
GILD vs MRK Comparison September 2026
Gilead Sciences, Inc. (NASDAQ: GILD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GILD stands at 188.7B. In comparison, MRK has a market cap of 367.3B. Regarding current trading prices, GILD is priced at $150.18 on the NASDAQ, while MRK trades at $148.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GILD currently has a P/E ratio of -390.28, whereas MRK's P/E ratio is 46.32. In terms of profitability, GILD's ROE is -0.16%, compared to MRK's ROE of +0.07%. Regarding short-term risk, GILD is less volatile compared to MRK. This indicates lower risk in terms of short-term price fluctuations for GILD.Check MRK's competition here
Novartis AG (NYSE: NVS)
GILD vs NVS Comparison September 2026
Gilead Sciences, Inc. (NASDAQ: GILD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GILD stands at 188.7B. In comparison, NVS has a market cap of 279.3B. Regarding current trading prices, GILD is priced at $150.18 on the NASDAQ, while NVS trades at $144.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GILD currently has a P/E ratio of -390.28, whereas NVS's P/E ratio is 16.91. In terms of profitability, GILD's ROE is -0.16%, compared to NVS's ROE of +0.30%. Regarding short-term risk, GILD is more volatile compared to NVS. This indicates higher risk in terms of short-term price fluctuations for GILD.Check NVS's competition here
AstraZeneca PLC (NYSE: AZN)
GILD vs AZN Comparison September 2026
Gilead Sciences, Inc. (NASDAQ: GILD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GILD stands at 188.7B. In comparison, AZN has a market cap of 257.9B. Regarding current trading prices, GILD is priced at $150.18 on the NASDAQ, while AZN trades at $163.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GILD currently has a P/E ratio of -390.28, whereas AZN's P/E ratio is 17.96. In terms of profitability, GILD's ROE is -0.16%, compared to AZN's ROE of +0.22%. Regarding short-term risk, GILD is more volatile compared to AZN. This indicates higher risk in terms of short-term price fluctuations for GILD.Check AZN's competition here
Amgen Inc. (NASDAQ: AMGN)
GILD vs AMGN Comparison September 2026
Gilead Sciences, Inc. (NASDAQ: GILD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GILD stands at 188.7B. In comparison, AMGN has a market cap of 225.7B. Regarding current trading prices, GILD is priced at $150.18 on the NASDAQ, while AMGN trades at $418.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GILD currently has a P/E ratio of -390.28, whereas AMGN's P/E ratio is 18.69. In terms of profitability, GILD's ROE is -0.16%, compared to AMGN's ROE of +0.89%. Regarding short-term risk, GILD is more volatile compared to AMGN. This indicates higher risk in terms of short-term price fluctuations for GILD.Check AMGN's competition here
Novo Nordisk A/S (NYSE: NVO)
GILD vs NVO Comparison September 2026
Gilead Sciences, Inc. (NASDAQ: GILD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GILD stands at 188.7B. In comparison, NVO has a market cap of 171.9B. Regarding current trading prices, GILD is priced at $150.18 on the NASDAQ, while NVO trades at $38.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GILD currently has a P/E ratio of -390.28, whereas NVO's P/E ratio is 9.63. In terms of profitability, GILD's ROE is -0.16%, compared to NVO's ROE of +0.59%. Regarding short-term risk, GILD is more volatile compared to NVO. This indicates higher risk in terms of short-term price fluctuations for GILD.Check NVO's competition here
Pfizer Inc. (NYSE: PFE)
GILD vs PFE Comparison September 2026
Gilead Sciences, Inc. (NASDAQ: GILD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GILD stands at 188.7B. In comparison, PFE has a market cap of 163.7B. Regarding current trading prices, GILD is priced at $150.18 on the NASDAQ, while PFE trades at $28.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GILD currently has a P/E ratio of -390.28, whereas PFE's P/E ratio is 9.42. In terms of profitability, GILD's ROE is -0.16%, compared to PFE's ROE of +0.05%. Regarding short-term risk, GILD is more volatile compared to PFE. This indicates higher risk in terms of short-term price fluctuations for GILD.Check PFE's competition here
Bristol-Myers Squibb Company (NYSE: BMY)
GILD vs BMY Comparison September 2026
Gilead Sciences, Inc. (NASDAQ: GILD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GILD stands at 188.7B. In comparison, BMY has a market cap of 130.5B. Regarding current trading prices, GILD is priced at $150.18 on the NASDAQ, while BMY trades at $63.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GILD currently has a P/E ratio of -390.28, whereas BMY's P/E ratio is 10.77. In terms of profitability, GILD's ROE is -0.16%, compared to BMY's ROE of +0.47%. Regarding short-term risk, GILD is more volatile compared to BMY. This indicates higher risk in terms of short-term price fluctuations for GILD.Check BMY's competition here
GSK plc (NYSE: GSK)
GILD vs GSK Comparison September 2026
Gilead Sciences, Inc. (NASDAQ: GILD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GILD stands at 188.7B. In comparison, GSK has a market cap of 99.6B. Regarding current trading prices, GILD is priced at $150.18 on the NASDAQ, while GSK trades at $49.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GILD currently has a P/E ratio of -390.28, whereas GSK's P/E ratio is 10.73. In terms of profitability, GILD's ROE is -0.16%, compared to GSK's ROE of +0.24%. Regarding short-term risk, GILD is more volatile compared to GSK. This indicates higher risk in terms of short-term price fluctuations for GILD.Check GSK's competition here
Sanofi (NASDAQ: SNY)
GILD vs SNY Comparison September 2026
Gilead Sciences, Inc. (NASDAQ: GILD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GILD stands at 188.7B. In comparison, SNY has a market cap of 98.9B. Regarding current trading prices, GILD is priced at $150.18 on the NASDAQ, while SNY trades at $40.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GILD currently has a P/E ratio of -390.28, whereas SNY's P/E ratio is 8.97. In terms of profitability, GILD's ROE is -0.16%, compared to SNY's ROE of +0.06%. Regarding short-term risk, GILD is more volatile compared to SNY. This indicates higher risk in terms of short-term price fluctuations for GILD.Check SNY's competition here
Biogen Inc. (NASDAQ: BIIB)
GILD vs BIIB Comparison September 2026
Gilead Sciences, Inc. (NASDAQ: GILD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GILD stands at 188.7B. In comparison, BIIB has a market cap of 33.8B. Regarding current trading prices, GILD is priced at $150.18 on the NASDAQ, while BIIB trades at $225.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GILD currently has a P/E ratio of -390.28, whereas BIIB's P/E ratio is 14.44. In terms of profitability, GILD's ROE is -0.16%, compared to BIIB's ROE of +0.05%. Regarding short-term risk, GILD is more volatile compared to BIIB. This indicates higher risk in terms of short-term price fluctuations for GILD.Check BIIB's competition here
Horizon Therapeutics Public Limited Company (NASDAQ: HZNP)
GILD vs HZNP Comparison September 2026
Gilead Sciences, Inc. (NASDAQ: GILD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GILD stands at 188.7B. In comparison, HZNP has a market cap of 26.6B. Regarding current trading prices, GILD is priced at $150.18 on the NASDAQ, while HZNP trades at $116.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GILD currently has a P/E ratio of -390.28, whereas HZNP's P/E ratio is 61.86. In terms of profitability, GILD's ROE is -0.16%, compared to HZNP's ROE of +0.11%. Regarding short-term risk, GILD is more volatile compared to HZNP. This indicates higher risk in terms of short-term price fluctuations for GILD.Check HZNP's competition here
Grifols, S.A. (NASDAQ: GRFS)
GILD vs GRFS Comparison September 2026
Gilead Sciences, Inc. (NASDAQ: GILD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GILD stands at 188.7B. In comparison, GRFS has a market cap of 6.3B. Regarding current trading prices, GILD is priced at $150.18 on the NASDAQ, while GRFS trades at $7.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GILD currently has a P/E ratio of -390.28, whereas GRFS's P/E ratio is 8.51. In terms of profitability, GILD's ROE is -0.16%, compared to GRFS's ROE of +0.08%. Regarding short-term risk, GILD is more volatile compared to GRFS. This indicates higher risk in terms of short-term price fluctuations for GILD.Check GRFS's competition here
Organon & Co. (NYSE: OGN)
GILD vs OGN Comparison September 2026
Gilead Sciences, Inc. (NASDAQ: GILD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GILD stands at 188.7B. In comparison, OGN has a market cap of 3.6B. Regarding current trading prices, GILD is priced at $150.18 on the NASDAQ, while OGN trades at $13.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GILD currently has a P/E ratio of -390.28, whereas OGN's P/E ratio is 4.10. In terms of profitability, GILD's ROE is -0.16%, compared to OGN's ROE of +0.23%. Regarding short-term risk, GILD is more volatile compared to OGN. This indicates higher risk in terms of short-term price fluctuations for GILD.Check OGN's competition here
Amarin Corporation plc (NASDAQ: AMRN)
GILD vs AMRN Comparison September 2026
Gilead Sciences, Inc. (NASDAQ: GILD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GILD stands at 188.7B. In comparison, AMRN has a market cap of 274M. Regarding current trading prices, GILD is priced at $150.18 on the NASDAQ, while AMRN trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GILD currently has a P/E ratio of -390.28, whereas AMRN's P/E ratio is -132.50. In terms of profitability, GILD's ROE is -0.16%, compared to AMRN's ROE of -0.06%. Regarding short-term risk, GILD is more volatile compared to AMRN. This indicates higher risk in terms of short-term price fluctuations for GILD.Check AMRN's competition here
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA)
GILD vs MIRA Comparison September 2026
Gilead Sciences, Inc. (NASDAQ: GILD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GILD stands at 188.7B. In comparison, MIRA has a market cap of 38M. Regarding current trading prices, GILD is priced at $150.18 on the NASDAQ, while MIRA trades at $0.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GILD currently has a P/E ratio of -390.28, whereas MIRA's P/E ratio is -0.62. In terms of profitability, GILD's ROE is -0.16%, compared to MIRA's ROE of -1.07%. Regarding short-term risk, GILD is less volatile compared to MIRA. This indicates lower risk in terms of short-term price fluctuations for GILD.Check MIRA's competition here
Scilex Holding Company (NASDAQ: SCLX)
GILD vs SCLX Comparison September 2026
Gilead Sciences, Inc. (NASDAQ: GILD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GILD stands at 188.7B. In comparison, SCLX has a market cap of 38M. Regarding current trading prices, GILD is priced at $150.18 on the NASDAQ, while SCLX trades at $4.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GILD currently has a P/E ratio of -390.28, whereas SCLX's P/E ratio is -0.11. In terms of profitability, GILD's ROE is -0.16%, compared to SCLX's ROE of +1.90%. Regarding short-term risk, GILD is less volatile compared to SCLX. This indicates lower risk in terms of short-term price fluctuations for GILD.Check SCLX's competition here
Scilex Holding Company (NASDAQ: SCLXW)
GILD vs SCLXW Comparison September 2026
Gilead Sciences, Inc. (NASDAQ: GILD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GILD stands at 188.7B. In comparison, SCLXW has a market cap of 24.6M. Regarding current trading prices, GILD is priced at $150.18 on the NASDAQ, while SCLXW trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GILD currently has a P/E ratio of -390.28, whereas SCLXW's P/E ratio is N/A. In terms of profitability, GILD's ROE is -0.16%, compared to SCLXW's ROE of +1.90%. Regarding short-term risk, GILD is less volatile compared to SCLXW. This indicates lower risk in terms of short-term price fluctuations for GILD.Check SCLXW's competition here
BioDelivery Sciences Intl, Inc. Wrrt (NASDAQ: BDSIW)
GILD vs BDSIW Comparison September 2026
Gilead Sciences, Inc. (NASDAQ: GILD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GILD stands at 188.7B. In comparison, BDSIW has a market cap of 0. Regarding current trading prices, GILD is priced at $150.18 on the NASDAQ, while BDSIW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GILD currently has a P/E ratio of -390.28, whereas BDSIW's P/E ratio is -0.43. In terms of profitability, GILD's ROE is -0.16%, compared to BDSIW's ROE of +0.57%. Regarding short-term risk, GILD is less volatile compared to BDSIW. This indicates lower risk in terms of short-term price fluctuations for GILD.Check BDSIW's competition here
Clarus Therapeutics Holdings, Inc. (NASDAQ: CRXT)
GILD vs CRXT Comparison September 2026
Gilead Sciences, Inc. (NASDAQ: GILD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GILD stands at 188.7B. In comparison, CRXT has a market cap of 0. Regarding current trading prices, GILD is priced at $150.18 on the NASDAQ, while CRXT trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GILD currently has a P/E ratio of -390.28, whereas CRXT's P/E ratio is -0.02. In terms of profitability, GILD's ROE is -0.16%, compared to CRXT's ROE of -4.63%. Regarding short-term risk, GILD is less volatile compared to CRXT. This indicates lower risk in terms of short-term price fluctuations for GILD.Check CRXT's competition here